PrimeraDX, Inc.

PrimeraDx is a molecular diagnostics company that has developed, and commercialized, a novel, clinical platform which combines PCR with capillary electrophoresis. The result of combining these two well-known technologies into a bench-top instrument is the ability to deliver highly multiplexed and quantitative, answers to the clinic. The company is pursuing a two-pronged strategy to sell the system in an Open Platform Mode to clinical labs and to collaborate with pharmaceutical companies to develop high-value companion diagnostic products. Users can easily design complex multi-modal assays that test for disparate target types, like SNPs, expression biomarkers, microRNAs and fusion genes. PrimeraDx’s technology represents the next generation of quantitative PCR. www.MultiplexPCR.com